EX-99.1 2 ex99-1.htm Exhibit 99.1 Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025 Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 million Management continues to drive revenues and efficiencies Company achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improve Recurring technology fees, existing and new customer sales see continued growth Reduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last year Gross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last year Recurring Technology Fee revenue comprised 94% of total revenue with an 81.4% gross profit percentage Net loss attributable to common decreased 56.7% to $1.32 million Management will host its Q3 Fiscal Year 2025 Financial Results Call on Thursday, February 20th at 5:30 p.m. ET REDWOOD CITY, Calif. - …
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Biotricity Inc.
BTCYOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 20, 2025, Biotricity Inc. (the “Company”) issued a press release announcing the Company’s financial results for the period ended December 31, 2024. The press release is attached hereto as Exhibit 99.1.…
Company context
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.